Nanomaterials and Ethical Issues

  • Oodhimalai Elango Santhini
  • Selvaraj Dinesh Kirupha


Even after many discoveries and inventions of new nanomaterial devices for biomedical applications, still there were no stringent rules and regulations framed for the pharmaceutical products or the biomedicines developed from it. As a result, there was a bridge gap between biomedical advancement and clinical trials. This chapter discusses about the nanomaterial’s advancement, importance and its key role in the development of novel and improvised biomedical devices for many health-related issues in human body. There was a sharp edge of advancement with many novel inventions, at the same time there was a lack in discipline in the ethical issues and advancement related to it. Hence this chapter clearly connects the bridge between the issues and presented some improvisations for the development of nanobiomedical devices and their ethical issues.


Nanomaterials Biomedical devices Ethical issues Regulations Guidelines 


  1. Arts JHE, Hadi M, Irfan M, Keene AM, Kreiling R, Lyon D, Maier M, Michel K, Petry T, Sauer UG, Wiench K, Wohlleben W, Landsiedel R, Warheit D (2015) A decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping). Regul Toxicol Pharm 71:S1–S27CrossRefGoogle Scholar
  2. ASTM E2524 – 08 (2013) Standard test method for analysis of hemolytic properties of nanoparticles.
  3. ASTM E2865 – 12 (2018) Standard guide for measurement of electrophoretic mobility and zeta potential of nanosized biological materials.
  4. ASTM E3143 – 18b. Standard practice for performing cryo-transmission electron microscopy of liposomes.
  5. ASTM WK54872. New test method for measuring the size of nanoparticles in aqueous media using dynamic light scattering.
  6. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR (2016) Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm Res. 33(10):2373–2387CrossRefGoogle Scholar
  7. Caster JM, Patel AN, Zhang T, Wang A (2017) Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(1).
  8. Centerwatch (2017) FDA approved drugs. Accessed 25 Oct 2017.
  9. Clichici S and Filip A (2015) Nanomaterials—toxicity and risk assessment. In In vivo assessment of nanomaterials toxicity. Licensee InTech.Google Scholar
  10. Food and Drug Administration (2017) Novel drug approvals for 2017. Oct 20.Google Scholar
  11. Jones C, Grainger DW (2009) In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev. 61(6):438–456CrossRefGoogle Scholar
  12. Kuzma J, Priest S (2010) Nanotechnology, risk and oversight: learning lessons from related emerging technologies. Risk Anal 30(11):1688–1698CrossRefGoogle Scholar
  13. OECD (1984) Test no. 207. OECD guideline for the testing of chemicals –
  14. OECD (2004b) Test no. 209. OECD principles of corporate governance – 2004b Edition.
  15. OECD (2013) Test no. 246. OECD guidelines for the testing of chemicals, section 2. Test no. 236: fish embryo acute toxicity (FET) test.
  16. OECD (2010) Test no. 207. Earthworm, acute toxicity tests” A. Introduction, purpose.

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Oodhimalai Elango Santhini
    • 1
  • Selvaraj Dinesh Kirupha
    • 1
  1. 1.Centre of Excellence for Medical Textiles, The South India Textiles Research Association (SITRA)CoimbatoreIndia

Personalised recommendations